dc.contributor.author |
Levi, MS |
en |
dc.contributor.author |
Brimble, MA |
en |
dc.date.accessioned |
2011-09-18T23:29:37Z |
en |
dc.date.issued |
2004 |
en |
dc.identifier.citation |
Current Medicinal Chemistry 11(18):2383-2397 2004 |
en |
dc.identifier.issn |
0929-8673 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/8018 |
en |
dc.description.abstract |
The brain remains an area where little corrective surgery can be performed and the reversal of damage is almost impossible. Recently, reports of agents offering neuroprotection have begun to appear in the literature. The concept of neuroprotection is the administration of some agent, which should reverse some of the damage or prevent further damage. Some agents offer protection against cell degeneration to the neuronal cells. Still other agents specifically protect the dopamine neurons and the retina. The majority of neuroprotective agents are antioxidants. An immunosuppressive calcineurin inhibitor, NOS inhibitor, σ- 1 modulator, AMPA antagonist and Ca 2+ channel blocker have all shown neuroprotective activity. An estrogen agonist and two glycoprotein IIb/ IIIa antagonists also exhibit neuroprotective activity.Most of the synthetic compounds presented were not originally designed as neuroprotective agents but were found to possess neuroprotective activity in later studies. Many of these compounds are biologically active natural products, either plant extracts or endogenous peptides/proteins. This review will present the most recent reports on these agents. |
en |
dc.language |
EN |
en |
dc.relation.ispartofseries |
Current Medicinal Chemistry |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0929-8673/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
antioxidant |
en |
dc.subject |
neuroprotection |
en |
dc.subject |
calcineurin |
en |
dc.subject |
neuroprotective |
en |
dc.subject |
dopamine |
en |
dc.subject |
retina |
en |
dc.subject |
neurodegeneration |
en |
dc.subject |
stroke |
en |
dc.subject |
CENTRAL-NERVOUS-SYSTEM |
en |
dc.subject |
ACTIVATED PROTEIN-C |
en |
dc.subject |
CEREBRAL-ARTERY OCCLUSION |
en |
dc.subject |
AMPA RECEPTOR ANTAGONIST |
en |
dc.subject |
NEONATAL X-IRRADIATION |
en |
dc.subject |
RAT CORTICAL-NEURONS |
en |
dc.subject |
MITOCHONDRIAL PERMEABILITY TRANSITION |
en |
dc.subject |
TRANSIENT FOREBRAIN ISCHEMIA |
en |
dc.subject |
HUMAN-IMMUNODEFICIENCY-VIRUS |
en |
dc.subject |
TOLUENE INHALATION EXPOSURE |
en |
dc.title |
A Review of Neuroprotective Agents |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.2174/0929867043364522 |
en |
pubs.issue |
18 |
en |
pubs.begin-page |
2383 |
en |
pubs.volume |
11 |
en |
dc.rights.holder |
Copyright: 2004 Bentham Science Publishers Ltd. |
en |
dc.identifier.pmid |
15379704 |
en |
pubs.end-page |
2397 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Review |
en |
pubs.elements-id |
39925 |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Chemistry |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2010-09-01 |
en |
pubs.dimensions-id |
15379704 |
en |